Spread of segmental/multifocal idiopathic adult-onset dystonia to a third body site.


Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
06 2021
Historique:
received: 28 02 2021
revised: 08 04 2021
accepted: 20 04 2021
pubmed: 16 5 2021
medline: 27 1 2022
entrez: 15 5 2021
Statut: ppublish

Résumé

Adult-onset focal dystonia can spread to involve one, or less frequently, two additional body regions. Spread of focal dystonia to a third body site is not fully characterized. We retrospectively analyzed data from the Italian Dystonia Registry, enrolling patients with segmental/multifocal dystonia involving at least two parts of the body or more. Survival analysis estimated the relationship between dystonia features and spread to a third body part. We identified 340 patients with segmental/multifocal dystonia involving at least two body parts. Spread of dystonia to a third body site occurred in 42/241 patients (17.4%) with focal onset and 10/99 patients (10.1%) with segmental/multifocal dystonia at onset. The former had a greater tendency to spread than patients with segmental/multifocal dystonia at onset. Gender, years of schooling, comorbidity, family history of dystonia/tremor, age at dystonia onset, and disease duration could not predict spread to a third body site. Among patients with focal onset in different body parts (cranial, cervical, and upper limb regions), there was no association between site of focal dystonia onset and risk of spread to a third body site. Spread to a third body site occurs in a relative low percentage of patients with idiopathic adult-onset dystonia affecting two body parts. Regardless of the site of dystonia onset and of other demographic/clinical variables, focal onset seems to confer a greater risk of spread to a third body site in comparison to patients with segmental/multifocal dystonia at onset.

Sections du résumé

BACKGROUND
Adult-onset focal dystonia can spread to involve one, or less frequently, two additional body regions. Spread of focal dystonia to a third body site is not fully characterized.
MATERIALS AND METHODS
We retrospectively analyzed data from the Italian Dystonia Registry, enrolling patients with segmental/multifocal dystonia involving at least two parts of the body or more. Survival analysis estimated the relationship between dystonia features and spread to a third body part.
RESULTS
We identified 340 patients with segmental/multifocal dystonia involving at least two body parts. Spread of dystonia to a third body site occurred in 42/241 patients (17.4%) with focal onset and 10/99 patients (10.1%) with segmental/multifocal dystonia at onset. The former had a greater tendency to spread than patients with segmental/multifocal dystonia at onset. Gender, years of schooling, comorbidity, family history of dystonia/tremor, age at dystonia onset, and disease duration could not predict spread to a third body site. Among patients with focal onset in different body parts (cranial, cervical, and upper limb regions), there was no association between site of focal dystonia onset and risk of spread to a third body site.
DISCUSSION AND CONCLUSION
Spread to a third body site occurs in a relative low percentage of patients with idiopathic adult-onset dystonia affecting two body parts. Regardless of the site of dystonia onset and of other demographic/clinical variables, focal onset seems to confer a greater risk of spread to a third body site in comparison to patients with segmental/multifocal dystonia at onset.

Identifiants

pubmed: 33991781
pii: S1353-8020(21)00155-3
doi: 10.1016/j.parkreldis.2021.04.022
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

70-74

Investigateurs

Paola Cimino (P)
Sara Scannapieco (S)
Gina Ferrazzano (G)
Amelia Brigandì (A)
Francesco Habetswallner (F)
Angelo Pascarella (A)
Tamara Ialongo (T)
Marina Ramella (M)
Sonia Mazzucchi (S)
Vincenzo Moschella (V)

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Tommaso Ercoli (T)

Department of Medical Science and Public Health, Institute of Neurology, University of Cagliari, Italy.

Roberto Erro (R)

Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi (SA), Italy.

Giovanni Fabbrini (G)

Department of Human Neurosciences, Sapienza University of Rome, Viale dell'Università 30, 00185, Rome, Italy; IRCCS, Neuromed, Pozzilli, Italy.

Roberta Pellicciari (R)

Department of Basic Science, Neuroscience and Sense Organs, Aldo Moro University of Bari, 70124, Bari, Italy.

Paolo Girlanda (P)

Department of Clinical and Experimental Medicine, University of Messina, Italy.

Carmen Terranova (C)

Department of Clinical and Experimental Medicine, University of Messina, Italy.

Laura Avanzino (L)

Ospedale Policlinico San Martino - IRCCS, Genoa, Italy; Department of Experimental medicine, Section of Human Physiology, University of Genoa, Italy.

Francesca Di Biasio (F)

Ospedale Policlinico San Martino - IRCCS, Genoa, Italy.

Paolo Barone (P)

Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi (SA), Italy.

Marcello Esposito (M)

Clinical Neurophysiology Unit, Cardarelli Hospital, Naples, Italy.

Gabriella De Joanna (G)

Clinical Neurophysiology Unit, Cardarelli Hospital, Naples, Italy.

Roberto Eleopra (R)

SOC Neurologia, AOU S.Maria della Misericordia; Neurological Unit 1, Fondazione IRCSS. Istituto Neurologico "Carlo Besta", Milan, Italy.

Francesco Bono (F)

Center for Botulinum Toxin Therapy. Neurologic Unit. A.O.U. Mater domini, Catanzaro, Italy.

Lucia Manzo (L)

Center for Botulinum Toxin Therapy. Neurologic Unit. A.O.U. Mater domini, Catanzaro, Italy.

Anna Rita Bentivoglio (AR)

Fondazione Policlinico Universitario 'Agostino Gemelli' - IRCCS, Rome, Italy; Institute of Neurology, Università Cattolica del Sacro Cuore, Rome, Italy.

Martina Petracca (M)

Fondazione Policlinico Universitario 'Agostino Gemelli' - IRCCS, Rome, Italy.

Marcello Mario Mascia (MM)

Department of Medical Science and Public Health, Institute of Neurology, University of Cagliari, Italy.

Alberto Albanese (A)

Department of Neurology, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy.

Anna Castagna (A)

IRCCS, Fondazione Don Carlo Gnocchi, Milan, Italy.

Roberto Ceravolo (R)

Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Maria Concetta Altavista (MC)

Neurology Unit, San Filippo Neri Hospital ASL Roma 1, Roma, Italy.

Cesa Scaglione (C)

IRCCS Institute of Neurological Sciences, Bologna, Italy.

Luca Magistrelli (L)

Movement Disorders Centre, Neurology Unit, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy; PhD program in Clinical and Experimental Medicine and Medical Humanities, University of Insubria, Varese, Italy.

Maurizio Zibetti (M)

Department of Neuroscience 'Rita Levi Montalcini', University of Turin, Turin, Italy.

Laura Bertolasi (L)

Neurologic Unit, University Hospital, Verona, Italy.

Mario Coletti Moja (M)

Mauriziano hospital Umberto I, Torino, Italy.

Maria Sofia Cotelli (MS)

Neurology Unit, ASST Valcamonica, Esine, Italy.

Giovanni Cossu (G)

Neurology Service and Stroke Unit, Department of Neuroscience, AO Brotzu, Cagliari, Italy.

Brigida Minafra (B)

IRCCS Mondino Foundation, Pavia, Italy.

Antonio Pisani (A)

IRCCS Mondino Foundation, Pavia, Italy; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.

Salvatore Misceo (S)

Neurologic Unit, San Paolo Hospital, Bari, Italy.

Nicola Modugno (N)

IRCCS, Neuromed, Pozzilli, Italy.

Marcello Romano (M)

Neurology unit, AOOR Villa Sofia Cervello, Palermo, Italy.

Daniela Cassano (D)

Unit of Neurology, Ospedale Maria Vittoria, Turin, Italy.

Alfredo Berardelli (A)

Department of Human Neurosciences, Sapienza University of Rome, Viale dell'Università 30, 00185, Rome, Italy; IRCCS, Neuromed, Pozzilli, Italy.

Giovanni Defazio (G)

Department of Medical Science and Public Health, Institute of Neurology, University of Cagliari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH